A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression

Journal of Clinical Psychiatry

Volumn 72, Issue 4, 2011, Pages 473-479

  Fava, Maurizio ^a   Schaefer, Kendyl ^b   Huang, Holly ^b   Wilson, Amy ^b,c   Iosifescu, Dan V ^a   Mischoulon, David ^a   Wessel, Thomas C ^b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

^c FoldRx Pharmaceuticals Inc   (United States)

^d ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG RESPONSE; DYSPEPSIA; HAMILTON SCALE; HEADACHE; HUMAN; IMPOTENCE; INFECTION; INSOMNIA; INSOMNIA SEVERITY INDEX; MAJOR DEPRESSION; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NERVOUSNESS; PAIN; PHARYNGITIS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SIDE EFFECT; SOMATIZATION; SOMNOLENCE; TASTE DISORDER; XEROSTOMIA;

ADULT; ANXIETY; AZABICYCLO COMPOUNDS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 79955510041     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05131gry     Document Type: Article

References (38)

1. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry. 1983;44(8, pt 2):8-11. (Pubitemid 13037504)
2. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150(8):1257-1258. (Pubitemid 23218913)
3. Van Valkenburg C, Akiskal HS, Puzantian V, et al. Anxious depressions: Clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord. 1984;6(1):67-82. (Pubitemid 14158974)
4. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55(2):50-59. (Pubitemid 24081821)
5. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299-1308. (Pubitemid 39517160)
6. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51(13): 823-835. (Pubitemid 46354060)
7. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148(11):1512-1517.
8. Fava M, Uebelacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42(7):568-576. (Pubitemid 27425475)
9. Flint AJ, Rifat SL. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107-115. (Pubitemid 27157394)
10. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16(1):4-13. (Pubitemid 34977120)
11. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. (Pubitemid 351704490)
12. Bosworth HB, Hays JC, George LK, et al. Psychosocial and clinical predictors of unipolar depression outcome in older adults. Int J Geriatr Psychiatry. 2002;17(3):238-246. (Pubitemid 34232596)
13. Hettema JM. The nosologic relationship between generalized anxiety disorder and major depression. Depress Anxiety. 2008;25(4):300-316. (Pubitemid 351614565)
14. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060. (Pubitemid 43849658)
15. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551-562. (Pubitemid 351645051)
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
17. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370. (Pubitemid 13098606)
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
19. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. (Pubitemid 9136500)
20. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4): 297-307. (Pubitemid 32677404)
21. Cleary P, Guy W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res. 1977;1:115-120.
22. A receptor subtypes. Eur J Pharmacol. 2002;451(2):103-110. (Pubitemid 35253948)
23. A) receptor are different. J Med Chem. 2008;51(22):7243-7252.
24. Sieghart W. Structure, pharmacology, and function of GABAa receptor subtypes. Adv Pharmacol. 2006;54:231-263.
25. Smith WT, Londborg PD, Glaudin V, et al; Summit Research Network. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord. 2002;70(3):251-259. (Pubitemid 34790259)
26. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007; 24(7):487-494. (Pubitemid 350086262)
27. Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928-1936.
28. Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol. 2000;14(1):23-45. (Pubitemid 32193048)
29. Gerner RH, Fairbanks L, Anderson GM, et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry. 1984;141(12):1533-1540. (Pubitemid 15219750)
30. Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical gamma- aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999;56(11): 1043-1047. (Pubitemid 29526389)
31. Sanacora G, Mason GF, Rothman DL, et al. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159(4):663-665. (Pubitemid 34274953)
32. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61(7):705-713. (Pubitemid 38890805)
33. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998;95(6):3239-3244. (Pubitemid 28135886)
34. Ketter TA, Wang PW. The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry. 2003; 64(suppl 3):15-20. (Pubitemid 36389867)
35. Moragues N, Ciofi P, Tramu G, et al. Localisation of GABAa receptor e-subunit in cholinergic and aminergic neurones and evidence for co-distribution with the 0-subunit in rat brain. Neuroscience. 2002; 111(3):657-669. (Pubitemid 34521903)
36. Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med. 2007;3(1):48-55. (Pubitemid 46761009)
37. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1402-1410. (Pubitemid 44901014)
38. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495. (Pubitemid 41671203)